ClinicalTrials.gg
CompletedNCT00113555ACTUpdated Jul 9, 2018Results posted

Adjustable Continence Therapy (ACT) Device for the Treatment of Female Stress Urinary Incontinence

An interventional study of ACT (Adjustable Continence Therapy) in Urinary Incontinence, sponsored by Uromedica. Completed at 7 sites in 2 countries. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-07-09.

Sponsored by Uromedica · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
221
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 293 studies in Urinary Incontinence with a site in United States — 33 open to participants now, 47 under way, 3 of them phase 3. Urinary Incontinence · United States.

Enrollment
60th of 249
221 · median 75
Started
2001
the only one that year
No phase
144 of 293
21 open now
Registered
10th of 293
by date

Among the 293 studies in Urinary Incontinence with a site in United States, this one is the 60th largest by enrollment of the 249 interventional ones that give a count, is the only one that started in 2001, is one of 144 with no phase, and was the 10th registered.

Urinary Incontinence

986 studies on the registry are indexed under Urinary Incontinence; 184 are open to participants now.

Browse Urinary Incontinence studies →

Open to participants now

33 of the 293 studies in Urinary Incontinence with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 113 Urinary Incontinence studies recruiting now, 63 (56%) set no upper age limit and 35 (31%) stop at 75 or younger; 15 take children under 18; 28 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies in Urinary Incontinence with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and effectiveness of a minimally invasive surgical procedure in up to 160 implanted female patients in which two adjustable balloons (one on each side of the urethra) are implanted to treat urinary stress incontinence.

The results will be analyzed to demonstrate the effects of the device as well as its associated risks. Therapeutic success will be based on whether the patients demonstrate at least a one-grade (mean) reduction in the Stamey score at 12 months.

Read the detailed description

This is a multi-center, prospective, non randomized clinical trial comparing baseline data to the 12 month data. Urodynamic testing, pad weights and a direct visual stress test will be used to determine success along with the Stamey score.

03

Conditions studied

  • Urinary Incontinence

Browse trials for

Keywords

  • urinary incontinence
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women
  • 18 years or older
  • Diagnosed with stress urinary incontinence with or without urethral hypermobility
  • Willing to sign
  • Candidates for surgical intervention for stress incontinence
  • Negative urinalysis or urine culture within 2 weeks of implantation
  • Normal cystourethroscopy
  • Failed at least 6 months of previous treatments for stress urinary incontinence (e.g., exercise regimen, electrical stimulation, surgical procedures, etc.)
  • May have failed suspension or sling procedures

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating
  • of less than one year
  • Insulin dependant diabetic
  • Auto-immune disease
  • Undergoing radiation therapy
  • Active urinary tract infection
  • Detrusor instability to meds
  • Reduced bladder compliance
  • Significant bladder residual >100mls
  • Bladder cancer
  • Unsuccessfully treated bladder stones
  • Current urethral stricture preventing the passage of a 24 French endoscope
  • Neurogenic bladder
  • Uncorrected rectocele, cystocele, urethrocele, enterocele or pelvic prolapse of Grade 3 or higher
  • Prior pelvic radiotherapy
  • Artificial urinary sphincter implanted
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
221 participants (actual)

Study arms

  • Experimental
    Experimental

    Open Label Study, ACT (Adjustable Continence Therapy)

    Device: ACT (Adjustable Continence Therapy)

Interventions

  • DeviceACT (Adjustable Continence Therapy)

    surgically implanted device

06

What researchers measure

Primary outcomes

  1. Change of Stamey Grade From Baseline to 12 Months.

    The Stamey grade classifies the severity of stress incontinence in four possible grades from 0-3. Grade 0: no leaking, Grade 1: loss of urine with sudden increases of abdominal pressure: e.g. coughing, sneezing or laughing, Grade 2: loss of urine with lesser degrees of stress: e.g. walking or standing up, and Grade 3: loss of urine without any relation to physical activity or position, e.g. while lying in bed. The primary end point at 12 months is a mean change in Stamey Grade from baseline of greater than or equal to -1.

    Time frame: Baseline to 12 months

Secondary outcomes

  1. Incontinence Quality of Life (IQoL) Questionnaire

    Change on Incontinence Quality of Life (IQoL) Questionnaire from baseline to 12 months. 0 being lowest quality of life, 100 being highest quality of life.

    Time frame: Baseline to 12 months

  2. Incontinence Impact Questionnaire (IIQ-7)

    Incontinence Impact Questionnaire (IIQ-7) change from baseline to 12 months. Scores range from 0-100. 0 being impact from incontinence, 100 being most impacted from incontinence.

    Time frame: Baseline to 12 months

  3. Urinary Distress Inventory (UDI-6)

    Change on Urinary Distress Inventory (UDI-6) questionnaire from baseline to 12 months. 0 being not distressed, 100 being very distressed.

    Time frame: Baseline to 12 months

  4. Number of Incontinence Episodes Per Day (Voiding Diary)

    Change in Number of Incontinence Episodes Per Day from baseline to 12 months. 0 being the best.

    Time frame: Baseline to 12 months

  5. Number of Pads Changed Per Day (Voiding Diary)

    Change in Number of Pads Changed Per Day from baseline to 12 months. 0 pads changed a day being the best.

    Time frame: Baseline to 12 months

  6. Provocative Pad Weight

    Change in weight of pads (gm) from baseline to 12 months. 0 gm pad weight being the best.

    Time frame: Baseline to 12 months

07

Results

Posted Jun 4, 2018

Participant flow

A total of 10 investigational sites in US and 2 in Canada which were clinics,University hospitals or Research centers implanted patients in this study from the period 2001-2006.A total of 221 patients have been enrolled(218 with enrollment data) and 163 of those patients underwent an implant procedure.

Participant flow — Overall Study
MilestoneACT Adjustable Continence Therapy for Women
Started221
Treated162
Completed142
Not completed79
Withdrew: Baseline failure59
Withdrew: Permanently explanted7
Withdrew: Death1
Withdrew: Missed followup4
Withdrew: Lost to follow-up8

Outcome measures

PrimaryChange of Stamey Grade From Baseline to 12 Months.

The Stamey grade classifies the severity of stress incontinence in four possible grades from 0-3. Grade 0: no leaking, Grade 1: loss of urine with sudden increases of abdominal pressure: e.g. coughing, sneezing or laughing, Grade 2: loss of urine with lesser degrees of stress: e.g. walking or standing up, and Grade 3: loss of urine without any relation to physical activity or position, e.g. while lying in bed. The primary end point at 12 months is a mean change in Stamey Grade from baseline of greater than or equal to -1.

Time frame:
Baseline to 12 months
Reported as:
Mean · units on a scale
Change of Stamey Grade From Baseline to 12 Months.
units on a scaleExperimental
Change of Stamey Grade From Baseline to 12 Months.-1.17 (-1.33 to -1.01)
Statistical analysis
  • Experimental · Wilcoxon (Mann-Whitney) · p = <0.001 · Mean difference (net): -1.16 · 95% CI -1.325 to -1.003
SecondaryIncontinence Quality of Life (IQoL) Questionnaire

Change on Incontinence Quality of Life (IQoL) Questionnaire from baseline to 12 months. 0 being lowest quality of life, 100 being highest quality of life.

Time frame:
Baseline to 12 months
Reported as:
Mean · units on a scale
Incontinence Quality of Life (IQoL) Questionnaire
units on a scaleACT Adjustable Continence Therapy for Women
Incontinence Quality of Life (IQoL) Questionnaire28.63 ± 29.69
SecondaryIncontinence Impact Questionnaire (IIQ-7)

Incontinence Impact Questionnaire (IIQ-7) change from baseline to 12 months. Scores range from 0-100. 0 being impact from incontinence, 100 being most impacted from incontinence.

Time frame:
Baseline to 12 months
Reported as:
Mean · units on a scale
Incontinence Impact Questionnaire (IIQ-7)
units on a scaleACT Adjustable Continence Therapy for Women
Incontinence Impact Questionnaire (IIQ-7)-26.53 ± 33.07
SecondaryUrinary Distress Inventory (UDI-6)

Change on Urinary Distress Inventory (UDI-6) questionnaire from baseline to 12 months. 0 being not distressed, 100 being very distressed.

Time frame:
Baseline to 12 months
Reported as:
Mean · units on a scale
Urinary Distress Inventory (UDI-6)
units on a scaleACT Adjustable Continence Therapy for Women
Urinary Distress Inventory (UDI-6)-22.66 ± 24.47
SecondaryNumber of Incontinence Episodes Per Day (Voiding Diary)

Change in Number of Incontinence Episodes Per Day from baseline to 12 months. 0 being the best.

Time frame:
Baseline to 12 months
Reported as:
Mean · units on a scale
Number of Incontinence Episodes Per Day (Voiding Diary)
units on a scaleACT Adjustable Continence Therapy for Women
Number of Incontinence Episodes Per Day (Voiding Diary)-2.76 ± 5.06
SecondaryNumber of Pads Changed Per Day (Voiding Diary)

Change in Number of Pads Changed Per Day from baseline to 12 months. 0 pads changed a day being the best.

Time frame:
Baseline to 12 months
Reported as:
Mean · Number of Pads Changed per Day
Number of Pads Changed Per Day (Voiding Diary)
Number of Pads Changed per DayACT Adjustable Continence Therapy for Women
Number of Pads Changed Per Day (Voiding Diary)-1.59 ± 3.63
SecondaryProvocative Pad Weight

Change in weight of pads (gm) from baseline to 12 months. 0 gm pad weight being the best.

Time frame:
Baseline to 12 months
Reported as:
Mean · gm
Provocative Pad Weight
gmACT Adjustable Continence Therapy for Women
Provocative Pad Weight-31.03 ± 55.27

Adverse events

Collected over Entire Study December 2001 to November 2010 at Study Closure. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ACT Adjustable Continence Therapy for Women0/163 (0%)2/163 (1.2%)155/163 (95.1%)
Most frequent serious events
Most frequent serious events
EventACT Adjustable Continence Therapy for Women
Other (non-pelvic)Cardiac disorders2/163
port erosionSurgical and medical procedures1/163
Most frequent other events
Showing 10 of 15
Most frequent other events
EventACT Adjustable Continence Therapy for Women
Other (non-Pelvic)General disorders112/163
Other (Pelvic)General disorders75/163
UTIRenal and urinary disorders75/163
Pain/DiscomfortGeneral disorders51/163
Worsening IncontinenceRenal and urinary disorders35/163
Balloon MigrationGeneral disorders27/163
Urinary RetentionRenal and urinary disorders24/163
Port ErosionGeneral disorders21/163
Yeast InfectionRenal and urinary disorders21/163
PerforationGeneral disorders14/163

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Experimental
<=18 years0
Between 18 and 65 years39
>=65 years123
Age, Continuous
Age, Continuous(years)Experimental
Mean67.6 ± 11.6
Sex: Female, Male
Sex: Female, Male(Participants)Experimental
Female162
Male0
Region of Enrollment
Region of Enrollment(participants)Experimental
United States137
Canada25
08

Study locations

7 sites
  • Kaiser Permanente
    Los Angeles, California 90027, United States
  • Emory University School of Medicine
    Atlanta, Georgia 30322, United States
  • Lahey Clinic
    Burlington, Massachusetts 01805, United States
  • Metro Urology
    Plymouth, Minnesota 55441, United States
  • Kansas City Urology Care
    Kansas City, Missouri 64123, United States
  • Can-Med Clinical Research Inc.
    Victoria, British Columbia V8T5GI, Canada
  • CHUS-Fleurimont
    Fleurimont, Quebec J1H5N4, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2001, a primary completion of Jul 2008 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2018, 9 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2005
First posted
Jun 9, 2005
Start
Dec 2001
Primary completionActual
Jul 2008
CompletionActual
Nov 2010
Results first posted
Jun 4, 2018
Last update
Jul 9, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00113555
Lead sponsor
Uromedica
Responsible party
Sponsor
First posted
Jun 9, 2005
Start date
Dec 2001
Primary completion
Jul 2008
Completion
Nov 2010
Results posted
Jun 4, 2018
Last update
Jul 9, 2018

Study contacts

Tim Cook
study director · Uromedica, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion